Technological Advances in Glucose Management in Older Adults

Not Applicable

Completed

• Conditions: Older Adults; Type 1 Diabetes Mellitus; Hypoglycemia
• Interventions: Other: eCGM (enhanced CGM)

• Registration Number: NCT03078491
• Lead Sponsor: Joslin Diabetes Center

Brief Summary

This is a study to assess the effectiveness of CGM (Continuous Glucose Monitor), enhanced by a diabetes management platform (DMP), collectively called enhanced CGM (eCGM), in the care of older patients with T1D. The DMP includes an automated data transfer from CGM, insulin-delivery devices, and activity tracker to a clinical decision support system (CDS) that provides dosing adjustment recommendations based on that data to the healthcare team. In addition, the DMP includes on-demand education for patients and caregivers, and an interface for communication between providers, patients, and their caregivers.

Detailed Description

Hypoglycemia is a major and often devastating complication of T1D in the elderly. CGM has been shown to reduce the risk for hypoglycemia in adults with T1D including some more functional patients over 65 years old. However, the Medicare population is heterogeneous and may have age-related clinical and functional impairments that can impact self-care. These patients will require additional targeted guidance and support to fully realize the potential benefits of CGM. To address these age-specific barriers which could limit the effective use of CGM, in our planned RCT (Specific Aim 1) the use of CGM will be coupled with the DMP (Diabetes Management Platform), a tablet-based technology platform ( termed enhanced CGM (eCGM)). The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The use of the DMP is expected to help the less technologically proficient Medicare patients to derive benefit from CGM. Specific Aim 2 will involve extensive mixed methods research (including semi-structured interviews of patients and caregivers) directed at making an in-depth assessment of barriers to the use of diabetes technology in older adults. This investigation will provide the evidence-base for future improvements in both the technology and clinical approach to the training of older adults and their caregivers. Specific Aim 3 will involve a cost-effectiveness analysis of the technology system (CGM with DMP = enhanced CGM \[eCGM\]) used in the trial as well as quality of life measures, providing a foundation for decision-making on coverage.

Study Timeline

• Study First Submitted: 2017-02-21
• Study First Submitted QC: 2017-03-07
• Study First Posted: 2017-03-13
• Study Start: 2017-03-30
• Primary Completion: 2022-09-01
• Study Completion: 2022-10-01
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-22
• Last Update Posted: 2023-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• Patients with age ≥ 65 years
• Community-living
• Clinical diagnosis of T1D
• On multiple insulin injections (≥3 injection/s day) or insulin pump.

Exclusion Criteria

• Use of real-time CGM in past 2 years
• A1c > 10% (since individuals with very poor glycemic control usually have barriers to optimal self-care that preclude effective use of technology)
• Use of insulin pump that cannot be uploaded for CDS
• Unable or unwilling to perform task needed for study participation during the run-in period
• Severe vision or hearing impairment that could interfere with study tasks
• Need to use acetaminophen on regular basis (since can interfere with CGM accuracy)
• Living in an institutional setting (e.g. group homes, nursing homes)
• Terminal diseases with life expectancy < 1 year (e.g. malignancy)
• Severe comorbidities that prevent completing outcome measurements (e.g. severe dementia, severe vision impairment, severe functional disabilities, inability to perform basic activities of daily living)
• Alcohol or other drug abuse
• Conditions that impact wear of CGM (e.g. CHF with edema, skin conditions); and
• End stage renal insufficiency (eGFR<30), or on dialysis (since impact of fluid shift on sensor lag not clearly understood).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention	eCGM (enhanced CGM)	The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.

Primary Outcome Measures

Name	Time	Method
Change in duration of hypoglycemia	change of duration of hypoglycemia(minutes/day) from baseline to 6 months between intervention and control groups	Minutes per day CGM \< 70 mg/dL assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)

Secondary Outcome Measures

Name	Time	Method
Barriers and facilitators of CGM use	6 months	Mixed-method approach using semi-structured interviews to assess barriers and facilitators in those participants who fail the pretrial run-in and those who derive benefits from eCGM
Severe clinical hypoglycemia	change in severe clinical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups	Incidence of clinically severe hypoglycemia (requiring third party assistance or loss of consciousness) measured by clinical history,
Fasting and bedtime CGM glucose values per day	change in glucose values(mg/dl) from baseline to 6 months between intervention and control groups	Difference from fasting and bedtime CGM glucose values per day
Severe biochemical hypoglycemia	change in severe biochemical hypoglycemia (episodes per day) from baseline to 6 months between intervention and control groups	Incidence of severe biochemical hypoglycemia (defined as CGM below 54mg/dL for \> than 20 minutes) assessed over 2 weeks CGM use (blinded in the control arm; unblinded in the treatment arm)
Hemoglobin A1C	Change in A1C (%) from baseline to 6 months between intervention and control groups	A1C measured by laboratory test
Cost-effectiveness and cost-utility	6 months	cost-effectiveness and cost-utility of using eCGM versus usual care with self-monitoring glucose monitoring by calculating the incremental cost-effectiveness ratios

Trial Locations

Locations (1)

Joslin Diabetes Center; 🇺🇸 Boston, Massachusetts, United States